RPg Family Wealth Advisory’s Blueprint Medicines BPMC Stock Holding History

RPg Family Wealth Advisory’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-207	Closed	-$13.2K	–	105
2022 Q1	$13.2K	Hold	207	–	–	0.01%	242
2021 Q4	$22.2K	Hold	207	–	–	0.01%	215
2021 Q3	$21.3K	Hold	207	–	–	0.01%	222
2021 Q2	$18.2K	Buy	+207	New	+$19K	0.01%	232
2020 Q4	$14.6K	Hold	130	–	–	0.01%	258
2020 Q3	$12.1K	Hold	130	–	–	0.01%	261
2020 Q2	$10.1K	Sell	130 -65	-33%	-$4.4K	0.01%	278
2020 Q1	$11.4K	Sell	195 -51	-21%	-$3.28K	0.01%	242
2019 Q4	$19.7K	Buy	246 +25	+11%	+$1.87K	0.01%	217
2019 Q3	$16.2K	Hold	221	–	–	0.01%	249
2019 Q2	$20.8K	Hold	221	–	–	0.01%	216
2019 Q1	$17.7K	Buy	221 +32	+17%	+$2.37K	0.01%	238
2018 Q4	$10.2K	Hold	189	–	–	0.01%	223
2018 Q3	$14.8K	Buy	189 +27	+17%	+$1.88K	0.01%	216
2018 Q2	$10.3K	Hold	162	–	–	0.01%	225
2018 Q1	$14.9K	Hold	162	–	–	0.01%	213
2017 Q4	$12.2K	Hold	162	–	–	0.01%	248
2017 Q3	$11.3K	Buy	+162	New	+$8.66K	0.01%	263

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

RPg Family Wealth Advisory's BPMC Position: Q2 2022 in Review

RPg Family Wealth Advisory sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 207 shares — an estimated $13.2K sold.

RPg Family Wealth Advisory first reported a position in BPMC in Q3 2017 and held it in 18 quarters. The position peaked at $22.2K in Q4 2021. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

RPg Family Wealth Advisory reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
RPg Family Wealth Advisory sold 207 Blueprint Medicines shares in Q2 2022, an estimated $13.2K.
RPg Family Wealth Advisory first reported a position in Blueprint Medicines in Q3 2017 and held it in 18 quarters.
RPg Family Wealth Advisory's Blueprint Medicines position peaked at $22.2K in Q4 2021.
237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on RPg Family Wealth Advisory's 13F filing for Q2 2022, filed 12 Aug 2022.